홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Diisopropylcarbodiimide → [2-(ethyldisulfanyl)-6-methylphenyl] (3S)-3-[[(2S)-2-[[(2S)-3-methyl-2-[methyl-[(2S)-4-methyl-2-[methyl-[2-[[(2S)-2-[methyl-[(2S,3R)-2-[[(2S)-4-methyl-2-[methyl-[(2S)-3-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]butanoyl]amino]pentanoyl]amino]-3-trityloxybutanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]pentanoyl]amino]butanoyl]amino]-3-phenylpropanoyl]amino]-4-[methyl-[(2S)-1-oxo-1-[[(2S)-1-oxo-1-piperidin-1-ylpropan-2-yl]amino]-3-phenylpropan-2-yl]amino]-4-oxobutanoate

HRID 1482257
인쇄

반응식

HRID 1482257 반응식
[CH2:1]([S:3][S:4][C:5]1[CH:10]=[CH:9][CH:8]=[C:7]([CH3:11])[C:6]=1[OH:12])[CH3:2].C(=NC(C)C)=NC(C)C.[CH2:22]([C@@H:29]([C:86](=[O:150])[NH:87][CH2:88][C:89](=[O:149])[N:90]([CH3:148])[C@@H:91]([CH2:144][CH:145]([CH3:147])[CH3:146])[C:92](=[O:143])[N:93]([CH3:142])[C@@H:94]([CH:139]([CH3:141])[CH3:140])[C:95](=[O:138])[NH:96][C@@H:97]([CH2:131][C:132]1[CH:137]=[CH:136][CH:135]=[CH:134][CH:133]=1)[C:98](=[O:130])[NH:99][C@H:100]([C:105](=[O:129])[N:106]([CH3:128])[C@@H:107]([CH2:121][C:122]1[CH:127]=[CH:126][CH:125]=[CH:124][CH:123]=1)[C:108](=[O:120])[NH:109][C@@H:110]([CH3:119])[C:111](=[O:118])[N:112]1[CH2:117][CH2:116][CH2:115][CH2:114][CH2:113]1)[CH2:101][C:102](O)=[O:103])[N:30]([CH3:85])[C:31](=[O:84])[C@H:32]([C@H:62]([O:64][C:65]([C:78]1[CH:83]=[CH:82][CH:81]=[CH:80][CH:79]=1)([C:72]1[CH:77]=[CH:76][CH:75]=[CH:74][CH:73]=1)[C:66]1[CH:71]=[CH:70][CH:69]=[CH:68][CH:67]=1)[CH3:63])[NH:33][C:34](=[O:61])[C@H:35]([CH2:57][CH:58]([CH3:60])[CH3:59])[N:36]([CH3:56])[C:37](=[O:55])[C@H:38]([CH:52]([CH3:54])[CH3:53])[NH:39][C:40](=[O:51])[C@H:41]([CH3:50])[NH:42][C:43](=[O:49])[O:44][C:45]([CH3:48])([CH3:47])[CH3:46])[C:23]1[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=1>CN(C)C1C=CN=CC=1.ClCCl>[CH2:22]([C@@H:29]([C:86](=[O:150])[NH:87][CH2:88][C:89](=[O:149])[N:90]([CH3:148])[C@@H:91]([CH2:144][CH:145]([CH3:147])[CH3:146])[C:92](=[O:143])[N:93]([CH3:142])[C@@H:94]([CH:139]([CH3:141])[CH3:140])[C:95](=[O:138])[NH:96][C@@H:97]([CH2:131][C:132]1[CH:137]=[CH:136][CH:135]=[CH:134][CH:133]=1)[C:98](=[O:130])[NH:99][C@H:100]([C:105](=[O:129])[N:106]([CH3:128])[C@@H:107]([CH2:121][C:122]1[CH:123]=[CH:124][CH:125]=[CH:126][CH:127]=1)[C:108](=[O:120])[NH:109][C@@H:110]([CH3:119])[C:111](=[O:118])[N:112]1[CH2:117][CH2:116][CH2:115][CH2:114][CH2:113]1)[CH2:101][C:102]([O:12][C:6]1[C:7]([CH3:11])=[CH:8][CH:9]=[CH:10][C:5]=1[S:4][S:3][CH2:1][CH3:2])=[O:103])[N:30]([CH3:85])[C:31](=[O:84])[C@H:32]([C@H:62]([O:64][C:65]([C:66]1[CH:71]=[CH:70][CH:69]=[CH:68][CH:67]=1)([C:72]1[CH:73]=[CH:74][CH:75]=[CH:76][CH:77]=1)[C:78]1[CH:83]=[CH:82][CH:81]=[CH:80][CH:79]=1)[CH3:63])[NH:33][C:34](=[O:61])[C@H:35]([CH2:57][CH:58]([CH3:60])[CH3:59])[N:36]([CH3:56])[C:37](=[O:55])[C@H:38]([CH:52]([CH3:54])[CH3:53])[NH:39][C:40](=[O:51])[C@H:41]([CH3:50])[NH:42][C:43](=[O:49])[O:44][C:45]([CH3:46])([CH3:47])[CH3:48])[C:23]1[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 3

HCID 12734DiisopropylcarbodiimideHCID 896685262-(Ethyldisulfanyl)-6-methylphenolHCID 117735990(6S,9S,12S,15S,18S,24S,27S,30S,33S)-18,30-dibenzyl-12,24-diisobutyl-9,27-diisopropyl-2,2,6,11,17,23,26-heptamethyl-33-(methyl((S)-1-oxo-1-(((S)-1-oxo-1-(piperidin-1-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamoyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-15-((R)-1-(trityloxy)ethyl)-3-oxa-5,8,11,14,17,20,23,26,29,32-decaazapentatriacontan-35-oic acid

생성물 1

HCID 131736694
[2-(ethyldisulfanyl)-6-methylphenyl] (3S)-3-[[(2S)-2-[[(2S)-3-methyl-2-[methyl-[(2S)-4-methyl-2-[methyl-[2-[[(2S)-2-[methyl-[(2S,3R)-2-[[(2S)-4-methyl-2-[methyl-[(2S)-3-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]butanoyl]amino]pentanoyl]amino]-3-trityloxybutanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]pentanoyl]amino]butanoyl]amino]-3-phenylpropanoyl]amino]-4-[methyl-[(2S)-1-oxo-1-[[(2S)-1-oxo-1-piperidin-1-ylpropan-2-yl]amino]-3-phenylpropan-2-yl]amino]-4-oxobutanoate
수율 80%

시약·촉매·용매 2

HCID 142844-(Dimethylamino)pyridine촉매HCID 6344Dichloromethane용매

실험 절차

2-(Ethyldisulfanyl)-6-methylphenol separately synthesized according to a conventional method (J. AM. CHEM. SOC. 2009, 131, 5432-5437) (10.3 mg, 0.051 mmol), N,N′-methanediylidenebis(propan-2-amine) (8.0 ul, 0.051 mmol) and N,N-dimethylpyridin-4-amine (4.2 mg, 0.034 mmol) were added to a solution of (6S,9S,12S,15S,18S,24S,27S,30S,33S)-18,30-dibenzyl-12,24-diisobutyl-9,27-diisopropyl-2,2,6,11,17,23,26-heptamethyl-33-(methyl((S)-1-oxo-1-(((S)-1-oxo-1-(piperidin-1-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamoyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-15-((R)-1-(trityloxy)ethyl)-3-oxa-5,8,11,14,17,20,23,26,29,32-decaazapentatriacontan-35-oic acid (Boc-Ala-Val-MeLeu-Thr(Trt)-MePhe-Gly-MeLeu-MeVal-Phe-Asp-MePhe-Ala-piperidine, 60.9 mg, 0.034 mmol) synthesized by peptide synthesis by the Fmoc method previously described using Boc amino acid in place of Fmoc amino acid at the N-terminal in dichloromethane (300 ul), and the mixture was stirred at room temperature overnight. The reaction solution was then concentrated under reduced pressure and purified by reverse phase silica gel column chromatography (10 mM aqueous ammonium acetate solution/methanol=70/30→0/100) to afford 2-(ethyldisulfanyl)-6-methylphenyl (6S,9S,12S,15S,18S,24S,27S,30S,33S)-18,30-dibenzyl-12,24-diisobutyl-9,27-diisopropyl-2,2,6,11,17,23,26-heptamethyl-33-(methyl((S)-1-oxo-1-(((S)-1-oxo-1-(piperidin-1-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)carbamoyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-15-((R)-1-(trityloxy)ethyl)-3-oxa-5,8,11,14,17,20,23,26,29,32-decaazapentatriacontan-35-oate (Compound P-138) (53.8 mg, 80%).

후처리

  1. concentrationThe reaction solution was then concentrated under reduced pressure
  2. custompurified by reverse phase silica gel column chromatography (10 mM aqueous ammonium acetate solution/methanol=70/30→0/100)

출처 및 근거

ORD 기록
ord-452d4f10fbc649eb9a411ddd1a39a591
출처 데이터셋
uspto-grants-2016_08
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US09409952B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트